Prognostic value of PCSK9 levels in patients with non-ST elevation myocardial infarction undergoing percutaneous coronary intervention (PCI)

被引:4
|
作者
Wang, Jixiang [1 ,2 ]
Han, Peng [1 ,5 ]
Gao, Mingdong [2 ]
Xiao, Jianyong [2 ]
Li, Xiaowei [2 ]
Zhang, Nan [2 ]
Ma, Jing [3 ]
Cui, Zhuang [4 ]
Yao, Tingting [4 ]
Chen, Yang [4 ]
Gao, Jing [3 ,5 ,6 ]
Liu, Yin [2 ]
机构
[1] Tianjin Med Univ, 22 Qi Xiang Tai Rd, Tianjin 300070, Peoples R China
[2] Tianjin Chest Hosp, Dept Cardiol, 261 Tai Er Zhuang Rd, Tianjin 300222, Peoples R China
[3] Tianjin Chest Hosp, Cardiovasc Inst, 261 Tai Er Zhuang Rd, Tianjin 300222, Peoples R China
[4] Tianjin Med Univ, Sch Publ Hlth, Epidemiol & Biostat Inst, 22 Qi Xiang Tai Rd, Tianjin 300222, Peoples R China
[5] Tianjin Med Univ, Thorac ClinicalColl, 22 Qi Xiang Tai Rd, Tianjin 300070, Peoples R China
[6] Tianjin Univ, Chest Hosp, 92 Weijin Rd, Tianjin 300072, Peoples R China
关键词
non-ST-elevation myocardial infarction (NSTEMI); protein convertase subtilisin/kexin type 9 (PCSK9); prognosis; SUBTILISIN/KEXIN TYPE 9; LOW-DENSITY-LIPOPROTEIN; CARDIOVASCULAR EVENTS; LOW LDL; DISEASE; RISK; OUTCOMES; ALIROCUMAB; MUTATIONS;
D O I
10.1016/j.hjc.2021.05.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in predicting major adverse cardiovascular events (MACEs) in Non-ST elevation myocardial infarction (NSTEMI) patients is still an open question, and the PCSK9 concentration of clinical usefulness remains unknown in guiding treatment. Methods and results: A total of 272 patients with NSTEMI were included in our prospective observational cohort study. Patients were followed up for 1 year. Their baseline plasma PCSK9 levels were determined by enzyme-linked immunosorbent assay. Patients were divided into high, medium, and low PCSK9 groups. All patients followed up for the occurrence of MACEs and received PCI therapy after admission. The associations of PCSK9 with MACEs were evaluated. The results showed that the incidence of composite MACEs was greater at higher concentrations of PCSK9. PCSK9 level was related to the level of lipoproteins, high-sensitivity C-reactive protein (hs-CRP), platelet volume distribution width, and DDimer. There was also a statistically significant correlation between PCSK9 concentrations and the GRACE score. The Kaplan-Meier curves showed that patients with high PCSK9 level had lower event-free survival rate. The survival analysis indicated high level of PCSK9-predicted MACEs independently. Subgroup analysis demonstrated that the prognostic value of high PCSK9 level was greater for patients classified by the GRACE score as high risk. Conclusion: In an NSTEMI setting, the concentration of PCSK9 is associated with hypercoagulability and hyperinflammation. High levels of PCSK9 independently predict future MACEs in patients with NSTEMI, particularly those classified by the GRACE score as high risk. (c) 2021 Hellenic Society of Cardiology. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:22 / 31
页数:10
相关论文
共 50 条
  • [1] Prognostic value of PCSK9 Levels in Non-ST elevation myocardial infarction patients undergoing percutaneous coronary intervention
    Wang, J. -X.
    Han, P.
    Gao, M. -D.
    Xiao, J. -Y.
    Li, X. -W.
    Zhang, N.
    Ma, J.
    Cui, Z.
    Yao, T. -T.
    Chen, Y.
    Gao, J.
    Liu, Y.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1376 - 1376
  • [2] Prognostic Value of Metabolic Syndrome in Patients With Non-ST Elevated Myocardial Infarction Undergoing Percutaneous Coronary Intervention
    Zhao, Li-Hong
    Liu, Yin
    Xiao, Jian-Yong
    Wang, Ji-Xiang
    Li, Xiao-Wei
    Cui, Zhuang
    Gao, Jing
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [3] The lipid paradox in patients with non-ST elevation and ST elevation myocardial infarction and percutaneous coronary intervention
    Sia, C. H.
    Ho, A. F. W.
    Bulluck, H.
    Zheng, H. L.
    Foo, L. L.
    Chan, M. Y. Y.
    Hausenloy, D. J.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3364 - 3364
  • [4] Prognostic value of serum uric acid levels in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Oduncu, V.
    Erkol, A.
    Akgun, T.
    Tanboga, I. H.
    Karabay, C. Y.
    Bitigen, A.
    EUROPEAN HEART JOURNAL, 2012, 33 : 629 - 629
  • [5] THE IMPACT OF FRAILTY ON THE OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION (PCI) IN THE SETTING OF NON-ST ELEVATION MYOCARDIAL INFARCTION
    Yao, Zhihong
    Thackray, Simon
    Khurram, Anam
    HEART, 2021, 107 : A46 - A46
  • [6] In-Hospital Outcomes of Patients with Non-ST Elevation Myocardial Infarction Undergoing Early Invasive Percutaneous Coronary Intervention
    Sikandari, Faiza
    Irfan, Ghazala
    Kubra, Ghulam
    Shabeen, Mehwish
    Qayoom, Reema
    Hassan, Maroof
    Aamir, Kanwal Fatima
    PAKISTAN HEART JOURNAL, 2024, 57 (03): : 207 - 212
  • [7] Prognostic value of magnesium in serum of patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention
    陈明宇
    洪万紫
    余烊
    蒋磊
    熊思
    罗长军
    SouthChinaJournalofCardiology, 2018, 19 (03) : 167 - 171
  • [8] Assessment of the prognostic value of coronary angiography in patients with non-ST segment elevation myocardial infarction
    Maciejewski, Pawel
    Lewandowski, Pawel
    Wasek, Wojciech
    Budaj, Andrzej
    KARDIOLOGIA POLSKA, 2013, 71 (02) : 136 - 142
  • [9] Inverse prognostic value of post-percutaneous coronary intervention fractional flow reserve in patients with non-ST segment elevation myocardial infarction
    Nadir, M. Adnan
    HEART, 2017, 103 (07) : 564 - 564
  • [10] The Prognostic Value of the Advanced Lung Cancer Inflammation Index for Major Cardiovascular and Cerebrovascular Events in Patients with Non-ST Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
    Karaca, Mehmet
    Kalyoncuoglu, Muhsin
    Zengin, Ahmet
    Eren, Semih
    Keskin, Kivanc
    Oflar, Ersan
    Karatas, Mehmet Baran
    Calik, Ali Nazmi
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (05)